PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
42.52K
No peer data available for comparison.
-8.50K
No peer data available for comparison.
-1.41
No peer data available for comparison.
-41.31M
No peer data available for comparison.
-8.50K
No peer data available for comparison.
1.58M
No peer data available for comparison.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze DCF forecasts for the company and compare them with competitors.
81.00K
Worse than EXEL's revenue of 1.83B.
-92.14%
Worse than EXEL's revenue growth rate of 13.60%.
-51.13M
Worse than EXEL's ebitda of 196.60M.
-63123.46%
Worse than EXEL's ebitda margin of 10.74%.
-51.92M
Worse than EXEL's ebit of 170.88M.
-64098.77%
Worse than EXEL's ebit margin of 9.34%.
790.00K
Better than EXEL's depreciation of 25.72M.
76.68M
Worse than EXEL's total cash of 995.30M.
94662.96%
Better than EXEL's cash as percentage of revenue of 54.38%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
7.95M
Better than EXEL's accounts payable of 33.77M.
9818.52%
Worse than EXEL's payables as percentage of revenue of 1.85%.
-153.00K
Worse than EXEL's capital expenditure of -162.97M.
-188.89%
Better than EXEL's capex as percentage of revenue of -8.90%.
4.99%
Better than EXEL's weighted average cost of capital (wacc) of 6.62%.
5.02%
Better than EXEL's cost of equity of 6.67%.
4.08%
Better than EXEL's cost of debt of 4.26%.
-0.23
Better than EXEL's beta of 0.51.
30.07M
Better than EXEL's diluted shares outstanding of 321.46M.
1.57M
Better than EXEL's total debt of 189.94M.
49.31M
Worse than EXEL's total equity of 11.10B.
50.89M
Worse than EXEL's total capital of 11.29B.
3.09%
Worse than EXEL's debt weighting of 1.68%.
96.91%
Worse than EXEL's equity weighting of 98.32%.
-51.92M
Worse than EXEL's ebiat of 137.87M.
-53.46M
Worse than EXEL's unlevered free cash flow of -4.93M.
2.00%
Worse than EXEL's long-term growth rate of 4.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than EXEL's net debt of -73.05M.
71.33M
Worse than EXEL's equity value of 8.24B.
2.37
Worse than EXEL's equity value per share of 25.62.